AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of triple therapy (direct oral anticoagulation [DOAC] + dual antiplatelet therapy [DAPT]) followed by 12 months of dual therapy (DOAC + P2Y12 inhibitor) after percutaneous coronary intervention (PCI). The OPTIMA-AF study assessed whether a shorter regimen — 1 month of DOAC + P2Y12, followed by DOAC monotherapy — could maintain efficacy while reducing the bleeding risk.

This randomized trial, conducted in 75 centers in Japan, included 1088 patients with AF undergoing PCI. The primary endpoint (PEP) was a composite of death, myocardial infarction (MI), or stroke at 1 year. The safety endpoint was the incidence of bleeding or deterioration in quality of life over the same period.

All procedures used Xience stents and intravascular imaging (intravascular ultrasound [IVUS]/optical coherence tomography [OCT]) guidance. Patients received aspirin (ASA) + P2Y12 + DOAC during the periprocedural period. The design included analyses for noninferiority and superiority. Mean age was 75 years, 80% of subjects were men, 94.1% had chronic coronary syndromes, and clopidogrel was used as the P2Y12 inhibitor in 48.5% of cases.

Read also: AHA 2025 | CLOSURE-AF: Left Atrial Appendage Occlusion (LAAO) vs. Medical Therapy in Atrial Fibrillation with High Stroke and Bleeding Risk

In the PEP analysis, there was an absolute event difference of 0.9%, thus meeting the noninferiority criterion (4.5% [1 month] vs. 5.4% [12 months]; hazard ratio [HR] 1.20; 95% confidence interval [CI] 0.70–2.07; p=0.002). Regarding safety, the 1-month arm showed a significant reduction in clinically relevant bleeding (4.8% vs. 9.5%; HR 0.50; 95% CI 0.31–0.80; p=0.004), being superior in this aspect.

Conclusions

In AF patients undergoing PCI, a 1-month regimen of DOAC + P2Y12 inhibitor followed by DOAC monotherapy proved noninferior for ischemic events and halved the incidence of clinically relevant bleeding.

Presented by Yohei Sotomi during the Late-Breaking Science session at AHA 2025, New Orleans, USA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...